Deep Dive Into Bio-Techne Stock: Analyst Perspectives (4 Ratings)
Portfolio Pulse from Benzinga Insights
In the last three months, 4 analysts have published ratings on Bio-Techne (NASDAQ:TECH), with a mix of bullish, somewhat bullish, and indifferent perspectives. The average 12-month price target is $83.0, slightly up from the previous $82.67. Analysts' actions include maintaining, lowering, and raising ratings, reflecting their responses to market conditions and company performance. Bio-Techne has shown positive financial performance with a revenue growth rate of 0.88%, a net margin of 13.26%, and a low debt-to-equity ratio of 0.2.
August 13, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Techne (NASDAQ:TECH) has received mixed analyst ratings over the past three months, with an average 12-month price target of $83.0. The company's financial performance has been positive, with a revenue growth rate of 0.88% and a net margin of 13.26%. Analysts' actions include maintaining, lowering, and raising ratings, reflecting their responses to market conditions and company performance.
The mixed analyst ratings and slight increase in the average price target suggest a cautiously optimistic outlook for Bio-Techne. The company's strong financial performance, including revenue growth and high net margin, supports a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100